BIOCON LIMITED

The oral proteins and peptides market is projected to grow to $2.86 billion by 2028 at a CAGR of 22.4%, driven by factors like rising chronic diseases, biotechnology investments, and non-invasive treatments. Key advancements include novel oral peptides, AI in drug discovery, and oral insulin formulations.

Biocon Biologics Ltd announced FDA approval of YESINTEK (Ustekinumab-kfce), a biosimilar to Stelara, for treating Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis. The company had previously settled with Janssen to commercialize YESINTEK in the U.S. by February 2025.

Predictive biotechnology is transforming healthcare and drug development, driven by AI, machine learning, and predictive modeling. Despite challenges like financing and regulatory hurdles, the sector is poised for growth in 2024, supported by innovation and strong pipeline assets. At the Bengaluru Tech Summit 2024, Dr. Kiran Mazumdar-Shaw emphasized the importance of bioethics and bio-manufacturing for addressing global challenges. AI is revolutionizing biotech through drug discovery and precision medicine, while predictive biotechnology integrates biology, data analytics, and AI to improve scale and efficiency.

Bengaluru Tech Summit 2024, Asia’s largest tech conclave, will be held Nov 19-21 at Bangalore Palace, featuring international delegations, strategic roundtables, and a startup pavilion. Highlights include MoUs with Switzerland, Finland, and UAE, and sessions on AI, biotech, and global collaborations.

Biocon's Q2FY25 consolidated revenue was Rs. 3,623 crore with a net loss of Rs. 16 crore. Biosimilars grew 19%, driven by US oncology and insulins. Syngene returned to growth, while generics faced price and demand pressures. Biocon Biologics refinanced $1.1 billion debt, oversubscribed 3x, reflecting investor confidence.

Trastuzumab biosimilars market to grow from $4.27B in 2023 to $5.43B in 2024, reaching $14.69B by 2028, driven by market expansion, patent expirations, and competitive pricing.

Biocon Biologics publishes study in GaBI Journal, proposing 6 policy recommendations to boost biosimilar adoption in LMICs, aiming to improve access to affordable healthcare.

Union Minister Dr. Jitendra Singh announces 30 breakthrough biotech startups at Global Bio India 2024, highlighting India's bio economy growth from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030. The event, with participation from 30+ countries, 500+ exhibitors, and 5,000+ delegates, fosters business networking and investment opportunities in various biotech sectors.

Bicara Therapeutics raised $315 million in IPO to fund a pivotal study for its head and neck cancer therapy, ficerafusp alfa, which targets EGFR and TGF-beta signaling. The drug, combined with Keytruda, showed a 54% overall response rate in advanced HNSCC patients, with 64% in HPV-negative cases. A Phase 2/3 trial is planned for 2025.